bluebird bio poised to advance gene therapy pipeline

2 September 2014

US clinical-stage biotech firm bluebird bio (Nasdaq: BLUE) is advancing a pipeline focused on gene therapy, a rapidly expanding area that has attracted significant industry interest, note analysts at Edison Equity Research in a note on the company.

bluebird aims to offer one-time, transformative therapies for rare diseases, which should support premium pricing, if commercialized. Its two clinical programs, LentiGlobin and Lenti-D, have been granted orphan drug designation in the USA and Europe. A CAR-T oncology collaboration with industry leader Celgene validates the technology’s promise.

Promising early clinical data for orphan programs

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK